|
answer text |
<p>The licensed cannabis-based medicine epidyolex is prescribed routinely for three
forms of epilepsy, for patients aged two years old and above. However, clinical guidelines
from the National Institute for Health and Care Excellence demonstrate a clear need
for more evidence to support routine prescribing and funding decisions for unlicensed
cannabis-based medicines.</p><p>We continue to call on the manufacturers of these
products to conduct research, and we are working with regulatory, research, and National
Health Service partners to establish clinical trials to test the safety and efficacy
of these products, to enable evidence based prescribing decisions.</p>
|
|